Literature DB >> 19740380

Chimeric IgG4 PR3-ANCA induces selective inflammatory responses from neutrophils through engagement of Fcgamma receptors.

Abdullah Hussain1, Tanya Pankhurst, Margaret Goodall, Rachel Colman, Royston Jefferis, Caroline O S Savage, Julie M Williams.   

Abstract

Anti-proteinase 3 antibodies are implicated in the pathogenesis of small vessel vasculitis. These are primarily immunoglobulin G (IgG), with different subclasses predominating at different stages of disease. However, little is known of their respective roles in pathogenesis. We have previously shown that patient IgG4 was able to induce superoxide release from human neutrophils. To circumvent difficulties in separating the subclasses and additional differences in polyclonal patient antibodies we have generated monoclonal mouse/human IgG1 and IgG4 anti-proteinase 3 antibodies. Using these antibodies we have compared effects of IgG1 and IgG4 on human neutrophils in terms of superoxide release, cytokine production, degranulation and adhesion. Additionally we have investigated the interaction of the subclasses with Fc receptors expressed by the neutrophil. Chimeric antibodies were generated using human constant regions of each subclass and a variable region taken from a monoclonal antibody directed against proteinase 3. Superoxide release from neutrophils was measured by the reduction of ferricytochrome C, degranulation by the conversion of a synthetic colour substrate, cytokine release by interleukin-8 enzyme-linked immunosorbent assay, and adhesion by a flow-based adhesion assay. Fc receptor binding was assessed using blocking antibodies. The IgG4 anti-proteinase 3 was able to induce a dose-dependent release of superoxide, degranulation and adhesion. The antibody was not able to stimulate the secretion of interleukin-8. Fc receptors were essential for neutrophil stimulation and the constitutive Fc receptors were necessary for different stimulatory pathways. The IgG4 anti-proteinase 3 antibodies are able to stimulate neutrophils to undergo a pro-inflammatory response and may play a role in the pathogenesis of small vessel vasculitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740380      PMCID: PMC2767313          DOI: 10.1111/j.1365-2567.2009.03108.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG.

Authors:  Julie M Williams; Anne Ben-Smith; Peter Hewins; Stephen K Dove; Philip Hughes; Robert McEwan; Michael J O Wakelam; Caroline O S Savage
Journal:  J Am Soc Nephrol       Date:  2003-03       Impact factor: 10.121

2.  IgG4 associated autoimmune hepatitis: a differential diagnosis for classical autoimmune hepatitis.

Authors:  T Umemura; Y Zen; H Hamano; T Ichijo; S Kawa; Y Nakanuma; K Kiyosawa
Journal:  Gut       Date:  2007-05-15       Impact factor: 23.059

Review 3.  IgG4 breaking the rules.

Authors:  Rob C Aalberse; Janine Schuurman
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

4.  Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcgamma receptor ligation.

Authors:  A Ben-Smith; S K Dove; A Martin; M J Wakelam; C O Savage
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

5.  Differential mitogen-activated protein kinase stimulation by Fc gamma receptor IIa and Fc gamma receptor IIIb determines the activation phenotype of human neutrophils.

Authors:  P Y Coxon; M J Rane; D W Powell; J B Klein; K R McLeish
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

6.  Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders.

Authors:  E Brouwer; J W Tervaert; G Horst; M G Huitema; M van der Giessen; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

7.  Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18.

Authors:  Peter Hewins; Julie M Williams; Michael J O Wakelam; Caroline O S Savage
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

8.  Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass.

Authors:  M Holland; P Hewins; M Goodall; D Adu; R Jefferis; C O S Savage
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

9.  Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies.

Authors:  Y Sommarin; N Rasmussen; J Wieslander
Journal:  Exp Nephrol       Date:  1995 Jul-Aug

10.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

Authors:  M Brüggemann; G T Williams; C I Bindon; M R Clark; M R Walker; R Jefferis; H Waldmann; M S Neuberger
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  17 in total

1.  Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Silvia Ferrari; Kristina Palavra; Bernadette Gruber; Johanna A Kremer Hovinga; Paul Knöbl; Claudine Caron; Caroline Cromwell; Louis Aledort; Barbara Plaimauer; Peter L Turecek; Hanspeter Rottensteiner; Friedrich Scheiflinger
Journal:  Haematologica       Date:  2013-11-15       Impact factor: 9.941

2.  Immunoglobulin subclass determines ability of immunoglobulin (Ig)G to capture and activate neutrophils presented as normal human IgG or disease-associated anti-neutrophil cytoplasm antibody (ANCA)-IgG.

Authors:  T Pankhurst; G Nash; J Williams; R Colman; A Hussain; C Savage
Journal:  Clin Exp Immunol       Date:  2011-03-10       Impact factor: 4.330

Review 3.  Immunology of IgG4-related disease.

Authors:  E Della-Torre; M Lanzillotta; C Doglioni
Journal:  Clin Exp Immunol       Date:  2015-06-08       Impact factor: 4.330

Review 4.  Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.

Authors:  C O S Savage
Journal:  Clin Exp Immunol       Date:  2011-05       Impact factor: 4.330

5.  No overlap between IgG4-related disease and microscopic polyangiitis and granulomatosis with polyangiitis despite elevated serum IgG4 at diagnosis: a retrospective monocentric study.

Authors:  Juyoung Yoo; Sung Soo Ahn; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2018-12-14       Impact factor: 2.980

6.  A unique report: development of super anti-human IgG monoclone with optical density over than 3.

Authors:  Leili Aghebati Maleki; Behzad Baradaran; Jalal Abdolalizadeh; Fatemeh Ezzatifar; Jafar Majidi
Journal:  Adv Pharm Bull       Date:  2013-08-20

7.  Membranous glomerulonephritis with crescents.

Authors:  Caroline M F Barrett; Megan L Troxell; Christopher P Larsen; Donald C Houghton
Journal:  Int Urol Nephrol       Date:  2013-11-12       Impact factor: 2.370

8.  Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system.

Authors:  Mark A Little; Bahjat Al-Ani; Shuyu Ren; Hamad Al-Nuaimi; Maurilo Leite; Charles E Alpers; Caroline O Savage; Jeremy S Duffield
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

9.  Production and characterization of mouse monoclonal antibodies recognizing multiple subclasses of human IgG.

Authors:  Fatemeh Hajighasemi; Fazel Shokri
Journal:  Avicenna J Med Biotechnol       Date:  2010-01

10.  Increased IgG4-Positive Plasma Cells in Granulomatosis with Polyangiitis: A Diagnostic Pitfall of IgG4-Related Disease.

Authors:  Sing Yun Chang; Karina Keogh; Jean E Lewis; Jay H Ryu; Eunhee S Yi
Journal:  Int J Rheumatol       Date:  2012-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.